Advertisement

Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro

      Abstract

      Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), which has been shown to be a clinically effective treatment for erectile dysfunction. Its action results from increased levels of cyclic guanosine monophosphate (cGMP), which is normally degraded by PDE5. This cyclic nucleotide is a second messenger for nitric oxide, which is involved in the regulation of numerous functions, including vascular smooth muscle tone. In an attempt to better predict the effects of sildenafil on cardiovascular function, the distribution of PDE activity was determined with anti-PDE1 and anti-PDE5 antibodies in the human cardiac ventricle and saphenous vein, and in vitro studies were performed on the isolated human cardiac ventricle, corpus cavernosum, saphenous vein, and mesenteric artery as well as on rabbit aorta, dog coronary artery, dog trabecular tissue, and rabbit and human platelets. The major PDE activity in the human cardiac ventricle was shown to be calcium/calmodulin-dependent PDE1, but there was no detectable level of PDE5. In contrast, the human saphenous vein contained PDEs 1, 4, and 5, and the human mesenteric artery contained PDEs 1, 2, 3, 4, and 5. The distribution of PDE5 in the cardiovascular system is consistent with the observed pharmacodynamic and clinical effects of sildenafil. Sildenafil, unlike milrinone, a selective PDE3 inhibitor, had no effect on the isolated trabeculae carneae; this is consistent with the lack of PDE5 expression in cardiac myocytes. Sildenafil selectively increased cGMP levels in coronary vascular smooth muscle tissue but produced no change in cyclic adenosine monophosphate (cAMP) levels, which is consistent with the drug’s selectivity for PDE5. In phenylephrine-contracted isolated rabbit aortic rings, sildenafil enhanced the relaxation induced by the nitric oxide donor glyceryl trinitrate, suggesting that sildenafil may potentiate the hypotensive effects of nitric oxide donor agents on the vasculature, an effect that has been observed clinically. Human platelets were found to contain PDE5, which was inhibited by 50% (IC50) by sildenafil at a concentration of 6.3 nM, consistent with the IC50 value in the corpus cavernosum. Sildenafil alone had no direct effect on platelet function, but it potentiated the in vitro antiaggregatory activity of sodium nitroprusside on rabbit and human platelets. The pharmacodynamic and adverse event profiles observed in clinical trials with sildenafil are consistent with the in vitro profile of the tissue distribution of PDE5 and its known mechanism of action as a selective inhibitor of PDE5.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ballard S.A
        • Gingell C.J
        • Tang K
        • Turner L.A
        • Price M.E
        • Naylor A.M
        Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes.
        J Urol. 1998; 159: 2164-2171
        • Boolell M
        • Allen M.J
        • Ballard S.A
        • Gepi-Attee S
        • Muirhead G.J
        • Naylor A.M
        • Osterloh I.H
        • Gingell C
        Sildenafil.
        Int J Impot Res. 1996; 8: 47-52
        • Goldstein I
        • Lue T.F
        • Padma-Nathan H
        • Rosen R.C
        • Steers W.D
        • Wicker P.A
        Oral sildenafil in the treatment of erectile dysfunction.
        N Engl J Med. 1998; 338: 1397-1404
        • Jeremy J.Y
        • Ballard S.A
        • Naylor A.M
        • Miller M.A.W
        • Angelini G.D
        Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro.
        Br J Urol. 1997; 79: 958-963
        • Fischer T.A
        • Erbel R
        • Treese N
        Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.
        Drugs. 1992; 44: 928-945
        • Beavo J.A
        Cyclic nucleotide phosphodiesterases.
        Physiol Rev. 1995; 75: 725-748
        • Rybalkin S.D
        • Bornfeldt K.E
        • Sonnenburg W.K
        • Rybalkina I.G
        • Kwak K.S
        • Hanson K
        • Krebs E.G
        • Beavo J.A
        Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.
        J Clin Invest. 1997; 100: 2611-2621
        • Packham M.A
        • Mustard J.F
        Pharmacology of platelet-affecting drugs.
        Circulation. 1980; 62: V26-V41
        • Moreland R.B
        • Goldstein I
        • Traish A
        Sildenafil, a novel inhibitor of phosphodiesterase type 5 in human corpus cavernosum smooth muscle cells.
        Life Sci. 1998; 62: 309-318
        • Morales A
        • Gingell C
        • Collins M
        • Wicker P.A
        • Osterloh I.H
        Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction.
        Int J Impot Res. 1998; 10: 69-74
        • Vallance P
        • Collier J
        • Moncada S
        Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man.
        Lancet. 1989; 2: 997-1000
        • Umans J.G
        • Levi R
        Nitric oxide in the regulation of blood flow and arterial pressure.
        Annu Rev Physiol. 1995; 57: 771-790
        • Webb D.J
        • Freestone S
        • Allen M.J
        • Muirhead G.J
        Sildenafil citrate and blood-pressure–lowering drugs.
        Am J Cardiol. 1999; 83: 21C-28C
        • Sly M.K
        • Eberhart R.C
        • Prager M.D
        Anti-platelet action of nitric oxide and selective phosphodiesterase inhibitors.
        Shock. 1997; 8: 115-118